Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord Blood Serum in the Treatment of Ocular Surface Diseases (Pilot Study)
2008-005757-38Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Mar 2009
- Modality
- Stem Cell Therapies → Cell Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord blood serum in ocular surface disease (OSD), Corneal epithelial defect, ocular graft-versus-host disease (oGVHD) and 4 more, sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Corneal epithelial defect healing at 2 weeks and Corneal epithelial defect healing at 4 weeks. Started Mar 2009; status: completed.
02
Drugs
human umbilical cord blood serum
03
Conditions
ocular surface disease (OSD)Corneal epithelial defectocular graft-versus-host disease (oGVHD)primary Sjögren's syndromeCorneal structural change
Beyond the preview
Go deeper on 2008-005757-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005757-38.